title: Adrenomedullin Does Not Inhibit Human Platelet Aggregation.
abstract: BACKGROUND: Adrenomedullin (ADM) is a hypotensive peptide isolated from human pheochromocytoma extracts discovered in 1993 using an assay system designed to monitor its ability to increase rat platelet adenosine 3',5'-cyclic monophosphate (cAMP) levels. Physiological mediators that elevate cAMP levels, such as prostaglandin (PG)E(1) and PGI(2), have also been shown to inhibit platelet aggregation. Therefore, we have chosen to investigate the effect of ADM, a peptide shown to increase platelet cAMP levels, on human platelet aggregation. METHODS AND RESULTS: Platelet-rich plasma prepared from blood donors was incubated with ADM (10(-9)-10(-6) M) for 1 min at 37 degrees C before the addition of a submaximal dose of adenosine 5'-diphosphate (ADP). ADM did not alter the platelet aggregatory response to ADP. PGE(1), a substance known to inhibit ADP-induced platelet aggregation (10(-6) M), however, inhibited ADP-induced platelet aggregation. In addition, the ADM induced a dose-dependent relation in rings of human chorionic arteries. CONCLUSIONS: These data may be interpreted to suggest that human platelets do not possess a functional ADM receptor couple with adenylate cyclase.
authors.affiliation: Departments of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, USA
authors.initials: NK
authors.lastname: Schiller
authors.initials: HC
authors.lastname: Champion
authors.initials: SY
authors.lastname: Hugghins
authors.initials: AM
authors.lastname: Timothy
authors.initials: WA
authors.lastname: Murphy
authors.initials: DH
authors.lastname: Coy
authors.initials: JR
authors.lastname: Peter
authors.initials: PJ
authors.lastname: Kadowitz
authors.initials: DB
authors.lastname: McNamara